USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: SEQUOIA SCIENCES, INC.
City: SAINT LOUIS
State: MO
Zip+4: 63114-5760
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $371,067.00 3
STTR Phase I $194,500.00 2
STTR Phase II $1,160,988.00 1

Award List:

Rapid Identificatioin of Regulators of Apoptosis

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lu Zeng
Award Amount: $170,495.00
Abstract:
DESCRIPTION (provided by applicant): Inappropriate activation or inactivation of apoptosis (programmed cell death) can have devastating consequences, from neurodegenerative disease to cancer. This Phase I proposal tests the hypothesis that we can significantly increase the… More

Control of Biofilms by Natural Products

Award Year / Program / Phase: 2001 / STTR / Phase I
Agency: HHS
Research Institution: MONTANA STATE UNIVERSITY
Principal Investigator: John W. Costerton
Award Amount: $194,500.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The importance of Biofilms in chronic and treatment-resistant infectious disease, increasingly is clear. Biofilms also are a major problem in industrial processes. The focus of this proposal is to develop methods for discovering compounds… More

Novel Nematicides Exist as Minor Components in Plants

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: USDA
Principal Investigator: Gary R. Eldridge, President and Chief Scientific Officer
Award Amount: $80,000.00
Abstract:
Preliminary data confirm that novel nematicidal compounds exist in libraries of plant compounds. This project will screen libraries to discover and indentify novel nematicides.

The next generation of synthetically-accessible anticancer drugs exist at minor c

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Gary R. Eldridge
Award Amount: $120,572.00
Abstract:
DESCRIPTION (provided by applicant): Treating cancer is clearly a very difficult process, and while progress has been made, much work remains to be done. The failures of many seemingly promising compounds to meet expectations have taught us that we must ag gressively continue to develop new,… More